The Top 5 Analyst Questions From NeoGenomics's Q3 Earnings Call

NeoGenomics’ third quarter results were met with a negative market reaction, as shares declined following the announcement. Management attributed the quarter’s performance to robust growth in clinical test volumes and continued expansion in next-generation sequencing (NGS) revenues, which outpaced general industry trends. CEO Anthony Zook highlighted the successful integration of the Pathline acquisition and cited the company’s ability to deliver faster turnaround times and a broader test menu as factors boosting customer adoption, stating, “We again saw a sequential improvement in AUP, a record quarter for test volumes and NGS revenue growth of 24%.”

Is now the time to buy NEO? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From NeoGenomics’s Q3 Earnings Call

• David Westenberg (Piper Sandler) asked about the likelihood of PanTracer LBx generating 2025 revenue and the timing of MRD reimbursement; CFO Jeffrey Sherman clarified that revenue guidance did not require LBx reimbursement this year and that MRD contributions are expected mainly in 2026.
• Andrew Brackmann (William Blair) inquired about customer segments driving NGS share gains; Chief Commercial Officer Warren Stone emphasized new community oncology accounts and a compounding effect from repeat orders for recently launched products.
• Mason Carrico (Stephens) questioned whether NGS revenue growth was volume- or pricing-driven; Sherman responded that it was primarily volume-driven, with some benefit from higher average unit price (AUP).
• Thomas Stevens (TD Cowen) sought insight into the sustainability of growth in the core clinical (non-NGS) business; Stone attributed this to the protect, expand, acquire strategy and recent sales force expansion.
• Yuko Oku (Morgan Stanley) probed pharma interest in MRD following industry trial results; Stone described robust pharma sponsor interest but noted long lead times before revenue materializes.

Catalysts in Upcoming Quarters

Over the coming quarters, our analysts will closely monitor (1) the pace of adoption and reimbursement for both RaDaR ST and PanTracer LBx, (2) progress on operational streamlining through LIMS integration and lab automation, and (3) signs of stabilization or renewed growth in the pharma and nonclinical segments. The company’s execution in expanding its Northeast presence through Pathline and commercializing new assays will also be important markers.

NeoGenomics currently trades at $9.78, down from $10.15 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free for active Edge members).

High-Quality Stocks for All Market Conditions

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.